anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To assess congenital fetal bradyarrhythmias with regard to etiological causes, features, risk factors, and prognosis.
METHODS: This retrospective study involved fetuses with fetal bradyarrhythmias. All fetuses were evaluated by ultrasonography. Parental ECGs and family histories were obtained, and maternal autoantibodies were measured. Gestational age at diagnosis, fetal atrial and ventricular rates at presentation, type of bradyarrhythmias, the presence or absence of a congenital heart defect (CHD), fetal hydrops, fetal myocardial dysfunction, extra-cardiac abnormalities, maternal autoimmune diseases, maternal autoantibodies as well as prenatal treatment, and neonatal outcome were collected.
RESULTS: Of the 40 fetuses included in the study, 11 had maternal rheumatologic disease, 16 had complex cardiac anomalies such as left and right isomerism. Fetuses with CHD significantly differed from those without CHD with increased rates of extra-cardiac anomalies, hydrops, fetal deaths and shorter survival after 28 days (p<0.05). Survival was significantly better in fetuses with maternal rheumatic disease as compared with those with no maternal rheumatic disease (p<0.05). Maternal anti-arrhythmic therapy was administered in 11 fetuses. In utero maternal treatment resulted in no significant difference in the course of arrhythmia or hydrops in fetuses with or without maternal rheumatic disease (p<0.05). In regression analysis, the absence of fetal hydrops was the only independent factor associated with survival (p=0.04).
CONCLUSIONS: The course of bradyarrhythmias, along with survival, seems to be more favorable in fetuses with maternal rheumatic disease than in those with CHD, especially left and right isomerism. Hydrops was the sole independent factor associated with poor survival.
PURPOSE:A remedy for wound containing a specific naphthalene derivative as an active ingredient. CONSTITUTION:A remedy for wound, containing a compound shown by the formula I (X is group shown by the formula II, formula III, or formula IV) as an active ingredient. It is effective for remedying trauma, congelation, burn, hemmorhoides, gastric ulcer, etc. It can be administered orally, preferably administered parenterally, especially preferably administered in the form of external preparation. An ointment, gel, and suspension may be cited as the external preparation. The compound shown by the formula I together with another proper compounding agent is pulverized, and may be directly applied to an affected part. An amount of administration is 10mg-1g/day when the remedy is administered as an ointment, and it is applied to an affected part one - several times daily.
The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
BACKGROUND: Evaluation of standard echocardiographic examination with artificial intelligence may help in the diagnosis of myocardial viability and function recovery after acute coronary syndrome.
METHODS: Sixty-one consecutive patients with acute coronary syndrome were enrolled in the present study (43 men, mean age 61 ± 9 years). All patients underwent percutaneous coronary intervention (PCI). 533 segments of the heart echo images were used. After 12 ± 1 months of follow-up, patients had an echocardiographic evaluation. After PCI each patient underwent cardiac magnetic resonance (CMR) with late enhancement and low-dose dobutamine echocardiographic examination. For texture analysis, custom software was used (MaZda 5.20, Institute of Electronics).Linear and non-linear (neural network) discriminative analyses were performed to identify the optimal analytic method correlating with CMR regarding the necrosis extent and viability prediction after follow-up. Texture parameters were analyzed using machine learning techniques: Artificial Neural Networks, Namely Multilayer Perceptron, Nonlinear Discriminant Analysis, Support Vector Machine, and Adaboost algorithm.
RESULTS: The mean concordance between the CMR definition of viability and three classification models in Artificial Neural Networks varied from 42% to 76%. Echo-based detection of non-viable tissue was more sensitive in the segments with the highest relative transmural scar thickness: 51-75% and 76-99%. The best results have been obtained for images with contrast for red and grey components (74% of proper classification). In dobutamine echocardiography, the results of appropriate prediction were 67% for monochromatic images.
CONCLUSIONS: Detection and semi-quantification of scar transmurality are feasible in echocardiographic images analyzed with artificial intelligence. Selected analytic methods yielded similar accuracy, and contrast enhancement contributed to the prediction accuracy of myocardial viability after myocardial infarction in 12 months of follow-up.
PURPOSE:To obtain the title pharmaceutical preparation with high medicinal retainability by adding to a lyophilized or spray-dried pharmaceutical preparation of positively or negatively charged liposome an aqueous solution of a medicine charged opposite to the case with said liposome. CONSTITUTION:Firstly, a water dispersion of positively charged liposome prepared by mixing 10-30mol% of a lipid, as film component, to be positively charged (e.g. basic lipid, basic amino acid-based surfactant), or another water dispersion of negatively charged liposome prepared by mixing 10-30mol% of a lipid to be negatively charged (e.g. acidic phospholipid, fatty acid) is lyophilized or spray-dried. Thence, an aqueous solution of a medicine charged opposite to the case with said liposome is added to the resulting dried liposome pharmaceutical preparation, thus obtaining the objective liposome water dispersion with high medicinal retainability. The amount of the medicine in its aqueous solution is pref. <=1/2 (esp. <=1/3), in terms of ionic equivalent, of the amount of the charged lipid involved in the charge of said liposome.
The present invention provides chimeric viral vectors which have both the capacity to infect host cells efficiently and the capacity to integrate their genomic material into the host cell's genome. Therefore the invention provides such a chimeric viral vector which comprises a functional packaging signal derived from a first virus and an integration means derived from a second virus. Typically viruses capable of integrating their material into a host cell genome, preferably provided with additional genetic material introduced therein by recombinant means, do not have much room for insertion of such additional genetic material or are not very well capable of infecting every wanted host cell. Typically viruses that are very well capable of infecting many host cells either also do not have a high insertion capacity or do not integrate their genomic material provided with said additional genetic material into the host cell's genome. The present invention provides a solution to the problem of getting large inserts integrated into a host cell's genome at an efficient infection rate by combining the properties of efficiently infecting viruses with efficiently integrating viruses. A good working example of the present invention is provided in a combination of adenovirus and adeno associated virus.
BACKGROUND: Inflammatory bowel disease (IBD) greatly affects human quality of life. Mannose has been reported to be used to treat IBD, but the mechanism is currently unknown.
METHODS: C57/BL mice were used as research subjects, and the mouse acute colitis model was induced using dextran sulfate sodium salt (DSS). After oral administration of mannose, the body weights and disease activity index (DAI) scores of the mice were observed. The colon lengths, histopathological sections, fecal content microbial sequencing, colon epithelial inflammatory genes, and tight junction protein Occludin-1 expression levels were measured. We further used the feces of mice that had been orally administered mannose to perform fecal bacterial transplantation on the mice with DSS-induced colitis and detected the colitis-related indicators.
RESULTS: Oral administration of mannose increased body weights and colon lengths and reduced DAI scores in mice with DSS-induced colitis. In addition, it reduced the expression of colon inflammatory genes and the levels of serum inflammatory factors (TNF-α, IL-6, and IL-1β), further enhancing the expression level of the colonic Occludin-1 protein and alleviating the toxic response of DSS to the intestinal epithelium of the mice. In addition, gut microbial sequencing revealed that mannose increased the abundance and diversity of intestinal flora. Additionally, after using the feces of the mannose-treated mice to perform fecal bacterial transplantation on the mice with DSS-induced colitis, they showed the same phenotype as the mannose-treated mice, and both of them alleviated the intestinal toxic reaction induced by the DSS. It also reduced the expression of intestinal inflammatory genes (TNF-α, IL-6, and IL-1β) and enhanced the expression level of the colonic Occludin-1 protein.
CONCLUSION: Mannose can treat DSS-induced colitis in mice, possibly by regulating intestinal microorganisms to enhance the intestinal immune barrier function and reduce the intestinal inflammatory response.
Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
PURPOSE: A mixture of a Prunella vulgaris extract and an Artemisia argyi herb extract is provided to suppress PTP1B(protein tyrosine phosphatase B1), and to prevent or treat diabetes. CONSTITUTION: A composition for suppressing PTP1B contains a Prunella vulgaris extract and/or an Artemisia argyi herb extract in a ratio of 1:1. A drug composition contains the composition for suppressing PTP1B as an active ingredient. A health food composition contains the composition for suppressing PTP1B as an active ingredient. A method for preparing the composition for suppressing PTP1B comprises: a step of extracting Prunella vulgaris and Artemisia argyi herb with water and filtering; a step of concentrating the liquid; and a step of drying the concentrate. [Reference numerals] (AA,EE) Control group; (BB,GG) Artemisia argyi herb; (CC,FF) Prunella vulgaris; (DD,HH) Mixture of Prunella vulgaris and Artemisia argyi herb
BACKGROUND: Adenoma's detection rates have been reported to vary with the participation status of endoscopic nurses during colonoscopy. This meta-analysis was conducted to determine whether the participation of endoscopy nurses during colonoscopy contributed to the improved detection rate of polyps and adenomas.
METHODS: We retrieved English original research from PubMed, Embase, Web of Science, and Cochrane library databases and Chinese original research from the CNKI Data database. We searched for randomized controlled trials (RCTs) comparing the effect of participation of endoscopy nurses during colonoscopy of colorectal polyps and adenomas on polyp detection rates to that of nonparticipation. RevMan5.4 software was used to perform the meta-analysis.
RESULTS: This meta-analysis included 11 randomized controlled trials involving 8278 patients. The results showed no significant difference between colonoscopies performed by nurses and endoscopists, but colonoscopies performed by two nurses significantly improved the detection rate of polyps and adenomas. In the random effects model, there was a significant difference in PDR between the single-observation and dual-observation groups (RR, 1.27; 95%CI, 1.05, 1.54; Z = 2.51; P = 0.01). The ADR difference between the single observation group and the double observation group was statistically significant (RR, 1.15; 95%CI, 1.05, 1.26; Z = 2.91; P = 0.004).
CONCLUSION: Endoscopy nurses' participation in colonoscopy can improve the detection rate of polyps and adenomas, However, more research is needed to confirm the results.
The invention discloses an application of loureirin B in preparing a medicament for preventing and/or treating obesity. Compared with the prior art, the invention discloses a new medical application of loureirin B, and finds that the loureirin B has an excellent effect of preventing and/or treating obesity. According to the invention, researches show that the loureirin B can obviously inhibit the weight gain of high fat induced obesity. And lourerin B mainly reduces fat weight and has little effect on lean body mass. In addition, it can also significantly improve the basal metabolic rate and fat utilization rate of mice. The research of molecular level shows that the loureirin B can obviously improve the expression of a browning molecular marker of white adipose tissues and promote the browning of the white adipose tissues.
The embodiments herein provide a powdered composition of natural substances for controlling deficiencies in polypeptide alpha and beta hemoglobin chains and a diet plan for treating thalassemia patient. The composition comprises passargad powder, pars powder, purgative material, fumigation material, snuffing material, vinegar syrup and parsomash powder. The passargad powder is a stomach tonic and acts as anti-parasitic, anti-diarrheal, anti-dysentery, anti-bloating and anti-heartburn agents. The pars powder comprises sprouted grains for providing nutrition to cells. The purgative material is body purifier or detoxification agent and helps in motion and bowl movement. The vapor/fumigation material softens and reduces stickiness of sputum and removes sputum. The snuff helps in sneezing and removal of sputum. The vinegar syrup breaks down fat and removes toxins. The parsomash is an detoxification agent. The composition and dietary plan eliminates the need of bone marrow transplant, blood transfusion and defroxamin in thalassemia patients.
PURPOSE:To produce a cosmetic having excellent odor, taste, spreadability, smoothness, and the feeling to the skin, etc., by treating castor oil with a microbial strain belonging to yeasts and capable of producing gamma-decalactone using castor oil as a substrate, and using the treated castor oil having modified qualities such as flavor, physical properties, etc. as a component of the cosmetic. CONSTITUTION:Castor oil is treated (e.g. by the cultivation treatment) with a microbial strain belonging to yeasts and capable of producing gamma-decalactone using castor oil as a substrate, e.g. the strain belonging to Saccharomyces genus, Pichia genus, Hansenura genus, or Candida genus. The treated castor oil is separated and added to a base of a cosmetic to obtain a cosmetic free from the characteristic ill odor of castor oil, and having strong, long-acting, extremely agreeable sweet milk-creamy or ripened aromatic smell, refreshing feeling to the palate, and excellent feeling to the skin.
Toward the identification of genetic basis of complex traits, transcriptome-wide association study (TWAS) is successful in integrating transcriptome data. However, TWAS is only applicable for common variants, excluding rare variants in exome or whole-genome sequences. This is partly because of the inherent limitation of TWAS protocols that rely on predicting gene expressions. Our previous research has revealed the insight into TWAS: the 2 steps in TWAS, building and applying the expression prediction models, are essentially genetic feature selection and aggregations that do not have to involve predictions. Based on this insight disentangling TWAS, rare variants' inability of predicting expression traits is no longer an obstacle. Herein, we developed "rare variant TWAS," or rvTWAS, that first uses a Bayesian model to conduct expression-directed feature selection and then uses a kernel machine to carry out feature aggregation, forming a model leveraging expressions for association mapping including rare variants. We demonstrated the performance of rvTWAS by thorough simulations and real data analysis in 3 psychiatric disorders, namely schizophrenia, bipolar disorder, and autism spectrum disorder. We confirmed that rvTWAS outperforms existing TWAS protocols and revealed additional genes underlying psychiatric disorders. Particularly, we formed a hypothetical mechanism in which zinc finger genes impact all 3 disorders through transcriptional regulations. rvTWAS will open a door for sequence-based association mappings integrating gene expressions.
Patients undergo leukapheresis from which peripheral blood mononuclear cells are purified. T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for CEA. Cells are expanded in culture and returned to the patient by intraperitoneal infusion at specific cell doses. One anti-CEA CAR-T dose per patient is planned. Additional cycles may be administered at the discretion of the principal investigator. Normal peritoneal and tumor biopsies will be obtained at the time of the CAR-T infusion, on the final day of the treatment period, and during reporting interval #3.
PURPOSE: A preparing method of ephedra sinca nanoparticles for activity of skin aging inhibition for the anti-wrinkle activity is provided to remove the smell of the Ephedrae Herba characteristic and obtain the Ephedrae Herba particle without the break down of the active material of the Ephedrae Herba. CONSTITUTION: An Ephedrae Herba is shattered. The distilled water of drainage is to solvent and the pulverized Ephedrae Herba is hot water extraction performed in 60 degrees for 24 hours the low temperature. After the hot water extract is filtered to a vacuum filtering device and makes with the powder. The powder is warmed with the concentration of 1mg/ml in the distilled water. The chloroform flies and the multilayer of the lecithin are formed by using decompressor.
NEW MATERIAL:A mannan-bleomycin combined substance obtained by combining mannan with bleomycin using a omega-amino-lower-alkanoic acid as a spacer. USE:An anti-neoplastic agent. PREPARATION:For example, bread yeast mannan is dissolved in a distilled water adjusted to pH10.7 and a solution obtained by dissolving cyanogen bromide in a distilled water adjusted to pH10.7 is added thereto. The resultant mixture is then reacted for 6 hr while keeping pH to 10.7 using 1N sodium hydroxide. After adjusting pH to 9.0, omega-aminocaproic acid, etc., is then added and a reaction is carried out for 24hr while keeping pH to 9.0. After completion of the reaction, the reaction solution is purified and concentrated using the ultrafiltration method and its pH is adjusted to 5.5. An aqueous bleomycin solution is subsequently added thereto and a water soluble carbodiimide is added. The resultant mixture is reacted for 24hr while keeping pH to 5-6, thus obtaining the objective mannan-bleomycin combined substance.
The prophylactic Argon plasma coagulation (APC) of non-bleeding visible vessels seems not to have an additional advantage in the prevention of delayed post polypectomy bleeding in recently studies. However, immediate APC after endoscopic mucosal resection (EMR) may not mean the complete coagulation of exposed vessels because of injection material. The aim of this study was to evaluate the clinical feature of the exposed vessels in ulcer base over time after prophylactic APC in colonic EMR. Methods: This study was designed as a prospective study. Investigators excluded diminutive polyp, large polyp (\> 2cm), long stalk pedunculated polyp, and clear ulcer base after EMR. Between August 2013 and May 2014, patients who were enrolled underwent prophylactic APC for non-bleeding visible vessels after colonic endoscopic mucosal resection. After checking the complete coagulation of visible vessels, the numbers of visible vessel group were counted by lap of time such as 1, 3, 5, and 7 min in ulcer base.
The present invention relates to a pharmaceutical composition, a functional health food, and a feed composition, for innate immune-boosting and antiviral purposes, containing a typha extract as an active ingredient. The present invention further relates to a method for boosting innate immunity and increasing antiviral activities in animals, including a step of injecting the typha extract into animals requiring enhancement of innate immunity, not including human. According to the present invention, the typha composition for innate immune-boosting and antiviral purposes shows effectiveness in boosting innate immunity and antiviral activities, and thus the composition can be used for preventing and treating infectious disease caused by bacteria and virus. In addition, the typha composition can be widely used as drugs or functional health foods for boosting and regulating immunity in a patient with weakened or suppressed immunity, and also as feeds for innate immune-boosting and antiviral purposes for strengthening an anti-disease immune system in animals. Furthermore, the composition for innate immune-boosting and antiviral purposes, according to the present invention, barely causes toxicity or side effects. Thus, the composition can be used with ease even for a long period of time in order to prevent disease.
Methods for improving the accuracy of occlusion sensor baselines in an infusion pump are described. An infusion pump includes logic for making an antiratchet decision for determining whether a new administration set was installed after there has been access to the administration set. If so, then new occlusion sensor baselines are established. If not, then the current baselines are maintained. The antiratchet decision logic may depend upon the value of a baseline delta equal to a difference between the upstream sensor signal and the downstream sensor signal. In another aspect, an upstream occlusion sensor baseline is shifted in correspondence with decreases in the upstream sensor signal occurring while a pumping mechanism of the infusion pump is not operating to compensate for sensor signal drift.